Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer signs development and marketing agreement with Medivation
Under the terms of the agreement, Medivation will receive an up-front cash payment of $225 million. Medivation also is eligible to receive payments of up to $500 million
Under the terms of the agreement, Medivation will receive an up-front cash payment of $225 million. Medivation also is eligible to receive payments of up to $500 million
As part of this collaboration, Opexa and the Myelin Repair Foundation (MRF) will work to identify therapeutically relevant biomarkers in multiple sclerosis (MS) that may provide important insight
The AZ-004 clinical trial enrolled 344 schizophrenic patients with acute agitation at 24 US clinical centers. The trial was designed as an in-clinic, multi-center, randomized, double-blind, placebo-controlled study
Threshold sold 8.97 million shares of its common stock at $2.04 per share, and warrants to purchase up to 3.58 million shares of its common stock for gross
According to the company, the grant was provided to support development of additional formulations and smallpox-related indications for ST-246, Siga’s lead drug candidate. ST-246 is said to be
Neurotech is conducting two Phase II/III trials of NT-501 for the treatment of visual loss associated with retinitis pigmentosa (RP)-one consisting of patients with earlier stage disease (60
Corcept has previously published the results of studies in rats that demonstrated that CORLUX, a potent GRII (cortisol) receptor antagonist, both reduced the weight gain associated with the
Dr Connor joins Halozyme from Ardea Biosciences where he was senior vice president and chief scientific officer. His responsibilities will include leadership of Halozyme’s multiple biology and chemistry
The new drug application (NDA) will be subject to a standard review period of 10 months, with a targeted user fee deadline of April 30, 2009. According to
Innovent Oncology offers payers and oncologists solutions that combine evidence-based treatment guidelines, patient support services and advance care planning to improve clinical outcomes while addressing costs, the company